Eiger BioPharmaceuticals Inc (EIGRQ)
OTCMKTS: EIGRQ · Delayed Price · USD
0.00 (0.00%)
Jun 17, 2024, 12:00 AM EDT - Market open

Company Description

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases.

The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.

Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.

The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Eiger BioPharmaceuticals Inc
Eiger BioPharmaceuticals logo
Country United States
Founded 2008
Industry Biotechnology
Sector Healthcare
Employees 25
CEO David Cory

Contact Details

2155 Park Boulevard
Palo Alto, California 94306
United States
Phone 650-279-9845

Stock Details

Ticker Symbol EIGRQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001305253
Employer ID 36-1004130
SIC Code 2836

Key Executives

Name Position
Dr. David Apelian M.B.A., M.D., Ph.D. Chief Executive Officer and Director
William G. Kaichoff CPA Chief Financial Officer and Principal Financial and Accounting Officer
Christopher A. Kurtz Chief Technical Officer
James Vollins J.D. General Counsel, Chief Compliance Officer and Corporate Secretary

Latest SEC Filings

Date Type Title
Jun 14, 2024 8-K Current Report
May 28, 2024 8-K Current Report
May 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
May 8, 2024 8-K Current Report
May 2, 2024 8-K Current Report
Apr 29, 2024 10-K/A [Amend] Annual report
Apr 25, 2024 25-NSE Filing
Apr 8, 2024 10-K Annual Report
Apr 3, 2024 8-K Current Report
Apr 1, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405